Healthpeak Properties Analyst Rating Update: Wells Fargo Lowers Price Target

Wells Fargo analyst John Kilichowski has lowered the price target for Healthpeak Properties (DOC) from $20.00 to $18.00, a 10% decrease. The average target price for DOC is $21.85 with a high estimate of $26.00 and a low estimate of $18.00. The average brokerage recommendation is 2.2, indicating an "Outperform" status.

Healthpeak Properties Inc. (DOC), a fully integrated real estate investment trust (REIT) focused on healthcare discovery and delivery, has seen its stock price target lowered by Wells Fargo analyst John Kilichowski. The new target price is $18.00, a 10% decrease from the previous estimate of $20.00. The average target price for DOC is now $21.85, with a high estimate of $26.00 and a low estimate of $18.00. The average brokerage recommendation is 2.2, indicating an "Outperform" status [2].

The recent quarterly results of Healthpeak, released on July 24, showed a marginal decline in revenue year-over-year to $694.3 million, missing consensus estimates. However, the company's adjusted funds from operations (AFFO) per share increased by 2.2% to $0.46, meeting analyst expectations. The company's earnings surprise history is promising, with Healthpeak meeting or exceeding consensus estimates in each of the last four quarters [1].

Despite the positive earnings surprises, Healthpeak's stock has underperformed the broader market over the past 52 weeks. Shares of DOC have declined 20% while the S&P 500 Index has gained 21.1%. Additionally, DOC has lagged behind the Real Estate Select Sector SPDR Fund (XLRE) over the same period [1].

The analyst ratings for Healthpeak remain mixed. Among the 18 analysts covering the stock, the consensus rating is a "Moderate Buy," with 10 "Strong Buy," two "Moderate Buy," and six "Hold" ratings. On Aug. 1, RBC Capital analyst Michael Carroll maintained a "Buy" rating on DOC with a price target of $21, implying a 24.6% potential upside from the current levels [1].

Healthpeak faces mixed signals from both technical and fundamental perspectives. The company's stock has seen a recent price rise of 2.28%, but this appears to clash with a generally bearish sentiment reflected in key indicators and analyst expectations. The stock is in a volatile phase with a weak technical outlook, prompting traders to tread carefully. Despite this, institutional investors show cautious buying, with a high inflow ratio of 49.86%, while retail inflows sit at 48.84% [2].

Given the mixed signals and the recent price target reduction, investors are advised to consider waiting for a clearer directional signal before initiating new positions. The upcoming ex-dividend date on Aug. 18 offers short-term support, but traders are advised to wait for clearer signals amid volatile momentum [2].

References:
[1] https://www.inkl.com/news/healthpeak-properties-stock-analyst-estimates-ratings
[2] https://www.ainvest.com/news/stock-analysis-healthpeak-outlook-navigating-volatility-mixed-signals-2508/